Saama, a provider of AI-based solutions that accelerate clinical development and commercialization, has entered a newly expanded, multi-year agreement with Pfizer to help expedite clinical research.   The agreement represents the expansion of a strategic relationship that began in 2020 when Saama and Pfizer partnered to automate Pfizer’s data review processes with artificial intelligence (AI). The result of that initial collaboration was Smart Data Quality (SDQ), which significantly cut down t...